{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:58:49Z","timestamp":1774497529841,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872384"],"award-info":[{"award-number":["81872384"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672872"],"award-info":[{"award-number":["81672872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472386"],"award-info":[{"award-number":["81472386"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cost-effectiveness is a pivotal consideration for clinical decision making of high-tech cancer treatment in developing countries. Intensity-modulated proton radiation therapy (IMPT, the advanced form of proton beam therapy) has been found to improve the prognosis of the patients with paranasal sinus and nasal cavity cancers compared with intensity-modulated photon-radiation therapy (IMRT). However, the cost-effectiveness of IMPT has not yet been fully evaluated. This study aimed at evaluating the cost-effectiveness of IMPT versus IMRT for treatment decision making of paranasal sinus and nasal cavity cancers in Chinese settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 3-state Markov model was designed for cost-effectiveness analysis. A base case evaluation was performed on a patient of 47-year-old (median age of patients with paranasal sinus and nasal cavity cancers in China). Model robustness was examined by probabilistic sensitivity analysis, Markov cohort analysis and Tornado diagram. Cost-effective scenarios of IMPT were further identified by one-way sensitivity analyses and stratified analyses were performed for different age levels. The outcome measure of the model was the incremental cost-effectiveness ratio (ICER). A strategy was defined as cost-effective if the ICER was below the societal willingness-to-pay (WTP) threshold of China (30,828 US dollars ($) \/ quality-adjusted life year (QALY)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IMPT was identified as being cost-effective for the base case at the WTP of China, providing an extra 1.65 QALYs at an additional cost of $38,928.7 compared with IMRT, and had an ICER of $23,611.2 \/ QALY. Of note, cost-effective scenarios of IMPT only existed in the following independent conditions: probability of IMPT eradicating cancer \u22650.867; probability of IMRT eradicating cancer \u22640.764; or cost of IMPT \u2264 $52,163.9. Stratified analyses for different age levels demonstrated that IMPT was more cost-effective in younger patients than older patients, and was cost-effective only in patients \u226456-year-old.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite initially regarded as bearing high treatment cost, IMPT could still be cost-effective for patients with paranasal sinus and nasal cavity cancers in China. The tumor control superiority of IMPT over IMRT and the patient\u2019s age should be the principal considerations for clinical decision of prescribing this new irradiation technique.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07083-x","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T11:04:32Z","timestamp":1593169472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China"],"prefix":"10.1186","volume":"20","author":[{"given":"Guo","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Xiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Doyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Bondiau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Benezery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Fei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-8831","authenticated-orcid":false,"given":"Chao-Nan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"7083_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/hed.21830","volume":"34","author":"JH Turner","year":"2012","unstructured":"Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34:877\u201385. https:\/\/doi.org\/10.1002\/hed.21830.","journal-title":"Head Neck"},{"issue":"Supp l","key":"7083_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.canrad.2016.07.035","volume":"20","author":"G Peyraga","year":"2016","unstructured":"Peyraga G, Lafond C, Pointreau Y, Giraud P, Maingon P. Nasal cavity and paranasal sinus cancer. Cancer Radiother. 2016;20(Supp l):99\u2013103. https:\/\/doi.org\/10.1016\/j.canrad.2016.07.035.","journal-title":"Cancer Radiother."},{"key":"7083_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ijrobp.2006.09.023","volume":"67","author":"BS Hoppe","year":"2007","unstructured":"Hoppe BS, Stegman LD, Zelefsky MJ, Rosenzweig KE, Wolden SL, Patel SG, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting-the MSKCC experience. Int J Radiat Oncol Biol Phys. 2007;67:691\u2013702. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.09.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7083_CR4","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1002\/1097-0142(20011215)92:12<3012::aid-cncr10131>3.0.co;2-e","volume":"92","author":"P Dulguerov","year":"2001","unstructured":"Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. 2001;92:3012\u201329. https:\/\/doi.org\/10.1002\/1097-0142(20011215)92:12<3012::aid-cncr10131>3.0.co;2-e.","journal-title":"Cancer."},{"key":"7083_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.radonc.2014.08.024","volume":"113","author":"N Fukumitsu","year":"2014","unstructured":"Fukumitsu N, Ishikawa H, Ohnishi K, Terunuma T, Mizumoto M, Numajiri H, et al. Dose distribution resulting from changes in aeration of nasal cavity or paranasal sinus cancer in the proton therapy. Radiother Oncol. 2014;113:72\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2014.08.024.","journal-title":"Radiother Oncol"},{"key":"7083_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.ijrobp.2011.07.032","volume":"83","author":"N Fukumitsu","year":"2012","unstructured":"Fukumitsu N, Okumura T, Mizumoto M, Oshiro Y, Hashimoto T, Kanemoto A, et al. Outcome of T4 (International Union against Cancer staging system, 7th edition) or recurrent nasal cavity and paranasal sinus carcinoma treated with proton beam. Int J Radiat Oncol Biol Phys. 2012;83:704\u201311. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.07.032.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7083_CR7","doi-asserted-by":"publisher","unstructured":"Samir H Patel, Zhen Wang, William W Wong, Mohammad Hassan Murad, Courtney R Buckey, Khaled Mohammed, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis Lancet Oncol 2014;15:1027\u20131038. doi: https:\/\/doi.org\/10.1016\/S1470-2045(14)70268-2.","DOI":"10.1016\/S1470-2045(14)70268-2"},{"key":"7083_CR8","unstructured":"Proton Beam Therapy Model Policy. In: Model policies. American Society for Radiation Oncology. 2020. https:\/\/www.astro.org\/Daily-Practice\/Reimbursement\/Model-Policies\/Model-Policies\/. Accessed 14 June 2020."},{"key":"7083_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.radonc.2009.12.002","volume":"95","author":"A Peeters","year":"2010","unstructured":"Peeters A, Grutters JP, Pijls-Johannesma M, Reimoser S, De Ruysscher D, Severens JL, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010;95:45\u201353. https:\/\/doi.org\/10.1016\/j.radonc.2009.12.002.","journal-title":"Radiother Oncol"},{"key":"7083_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.semradonc.2012.11.005","volume":"23","author":"Y Lievens","year":"2013","unstructured":"Lievens Y, Pijls-Johannesma M. Health economic controversy and cost-effectiveness of proton therapy. Semin Radiat Oncol. 2013;23:134\u201341. https:\/\/doi.org\/10.1016\/j.semradonc.2012.11.005.","journal-title":"Semin Radiat Oncol"},{"key":"7083_CR11","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.1996.03540140060028","volume":"276","author":"LB Russell","year":"1996","unstructured":"Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1172\u20137.","journal-title":"JAMA."},{"key":"7083_CR12","first-page":"5","volume":"8","author":"L Gao","year":"1999","unstructured":"Gao L, Xu GZ, Hu YH. Epithelial nasal ethmoid sinus carcinoma (attached clinical and efficacy analysis of 231 cases). Chin J Radiat Oncol. 1999;8:5\u20138.","journal-title":"Chin J Radiat Oncol"},{"key":"7083_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.oraloncology.2017.09.017","volume":"74","author":"MC Ward","year":"2017","unstructured":"Ward MC, Shah C, Adelstein DJ, Geiger JL, Miller JA, Koyfman SA, et al. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer. Oral Oncol. 2017;74:49\u201355. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.09.017.","journal-title":"Oral Oncol"},{"key":"7083_CR14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/jamaoto.2015.1314","volume":"141","author":"CW Noel","year":"2015","unstructured":"Noel CW, Lee DJ, Kong Q, Xu W, Simpson C, Brown D, et al. Comparison of health state utility measures in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2015;141:696\u2013703. https:\/\/doi.org\/10.1001\/jamaoto.2015.1314.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"7083_CR15","first-page":"1","volume":"68","author":"E Arias","year":"2019","unstructured":"Arias E, Xu J, Kochanek KD. United States life tables, 2016. Natl Vital Stat Rep. 2019;68:1\u201366.","journal-title":"Natl Vital Stat Rep"},{"key":"7083_CR16","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jama.276.16.1339","volume":"276","author":"JE Siegel","year":"1996","unstructured":"Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339\u201341. https:\/\/doi.org\/10.1001\/jama.276.16.1339.","journal-title":"JAMA."},{"key":"7083_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3760\/cma.j.issn.0254-6450.2019.03.002","volume":"40","author":"HM Wang","year":"2019","unstructured":"Wang HM. Attaching importance to health of elderly population and promoting national healthy ageing actively in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40:259\u201365. https:\/\/doi.org\/10.3760\/cma.j.issn.0254-6450.2019.03.002.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"7083_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006;26:410\u201320. https:\/\/doi.org\/10.1177\/0272989X06290495.","journal-title":"Med Decis Mak"},{"key":"7083_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler HG, Kong SX, Gerth WC, Mavros P, J\u00f6nsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518\u201328. https:\/\/doi.org\/10.1111\/j.1524-4733.2004.75003.x.","journal-title":"Value Health"},{"key":"7083_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o","volume":"9","author":"CJ Murray","year":"2000","unstructured":"Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9:235\u201351. https:\/\/doi.org\/10.1002\/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o.","journal-title":"Health Econ"},{"key":"7083_CR21","unstructured":"Facilities under construction. Particle therapy centers. 2020. https:\/\/www.ptcog.ch\/index.php\/facilities-under-construction. Accessed 14 June 2020."},{"key":"7083_CR22","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/cncr.29882","volume":"122","author":"V Verma","year":"2016","unstructured":"Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost effectiveness studies of proton radiotherapy. Cancer. 2016;122:1483\u2013501. https:\/\/doi.org\/10.1002\/cncr.29882.","journal-title":"Cancer."},{"key":"7083_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2016.02.031","volume":"95","author":"RB Mailhot Vega","year":"2016","unstructured":"Mailhot Vega RB, Ishaq O, Raldow A. Establishing cost-effective allocation of proton therapy for breast irradiation. Int J Radiat Oncol Biol Phys. 2016;95:11\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.02.031.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7083_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.ijrobp.2018.04.018","volume":"101","author":"DJ Sher","year":"2018","unstructured":"Sher DJ, Tishler RB, Pham NL, Punglia RS. Cost-effectiveness analysis of intensity modulated radiation therapy versus proton therapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2018;101:875\u201382. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.04.018.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7083_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12885-019-5614-4","volume":"19","author":"LJ Liao","year":"2019","unstructured":"Liao LJ, Hsu WL, Lo WC, Cheng PW, Shueng PW, Hsieh CH. Health-related quality of life and utility in head and neck cancer survivors. BMC Cancer. 2019;19:425. https:\/\/doi.org\/10.1186\/s12885-019-5614-4.","journal-title":"BMC Cancer"},{"key":"7083_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12955-017-0748-z","volume":"15","author":"M Meregaglia","year":"2017","unstructured":"Meregaglia M, Cairns J. A systematic literature review of health state utility values in head and neck cancer. Health Qual Life Outcomes. 2017;15:174. https:\/\/doi.org\/10.1186\/s12955-017-0748-z.","journal-title":"Health Qual Life Outcomes"},{"key":"7083_CR27","doi-asserted-by":"publisher","first-page":"l1335","DOI":"10.1136\/bmj.l1335","volume":"364","author":"RE Taylor","year":"2019","unstructured":"Taylor RE. Holistic approach is needed to evaluate potential benefits of proton beam therapy. BMJ. 2019;364:l1335. https:\/\/doi.org\/10.1136\/bmj.l1335.","journal-title":"BMJ."},{"key":"7083_CR28","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1002\/cncr.28322","volume":"119","author":"RB Mailhot Vega","year":"2013","unstructured":"Mailhot Vega RB, Kim J, Bussi\u00e8re M, Hattangadi J, Hollander A, Michalski J, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer. 2013;119:4299\u2013307. https:\/\/doi.org\/10.1002\/cncr.28322.","journal-title":"Cancer."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07083-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07083-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07083-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T19:29:39Z","timestamp":1624649379000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07083-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7083"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07083-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-26223\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-26223\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"599"}}